Showing results (351-360 of 523) with videos related to
Sort By:
Pageof 53
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.Journal for Immunotherapy of Cancer|June 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLCMatthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLCLuc Friboulet, Daniel Barrios-Gonzales, Frédéric Commo, et al.European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancerFrancesco Facchinetti, Ludovic Lacroix, Laura Mezquita, et al.Clinical Lung Cancer|September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France StudyPierre Mordant, Solenn Brosseau, Bernard Milleron, et al.The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.European Journal of Cancer (Oxford, England : 1990)|December 14, 2020
Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC studyThierry J Molina, Maria V Bluthgen, Lara Chalabreysse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 TrialJulien Mazieres, Claire Lafitte, Charles Ricordel, et al.International Journal of Cancer|August 15, 2024
Clinical and molecular features of early onset pancreatic adenocarcinomaMaxime Rémond, Cristina Smolenschi, Anthony Tarabay, et al.Pageof 53